Hong Kong WD Pharmaceutical Co., Limited Report issue

For profit Phase 1
Founded: Hong Kong Hong Kong (2015)
Status: No NME R&D (2015)

Organization Overview

First Clinical Trial
2019
NCT03761004
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Hong Kong WD Pharmaceutical Co., Limited

Active Ingredients

Drugs in Phase 1 Trials (3)

carbidopa (sinemet) (4 trials)

dabigatran (pradaxa) (1 trial)

levodopa (larodopa) (4 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Parkinson Disease (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 5
  • # of Trial APIs: 3